HLB Genex (A187420) Stock Overview
Engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
A187420 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.
Read full narrativeHLB Genex, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,660.00 |
| 52 Week High | ₩3,785.00 |
| 52 Week Low | ₩2,210.00 |
| Beta | 0.16 |
| 1 Month Change | 1.92% |
| 3 Month Change | 1.53% |
| 1 Year Change | -24.00% |
| 3 Year Change | -39.95% |
| 5 Year Change | -71.24% |
| Change since IPO | -78.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| A187420 | KR Chemicals | KR Market | |
|---|---|---|---|
| 7D | -9.5% | 0.1% | 12.5% |
| 1Y | -24.0% | 76.7% | 176.4% |
Return vs Industry: A187420 underperformed the KR Chemicals industry which returned 78.9% over the past year.
Return vs Market: A187420 underperformed the KR Market which returned 173% over the past year.
Price Volatility
| A187420 volatility | |
|---|---|
| A187420 Average Weekly Movement | 7.0% |
| Chemicals Industry Average Movement | 9.4% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A187420 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A187420's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 79 | Eui-Joong Kim | hlbgenex.com |
HLB Genex, Inc. engages in the research and development, production, import/export, and sale of enzymes and fermentation products in South Korea and internationally. Its industrial special enzyme products include lactase; catalase for use in semiconductor industry; and proteinase K for molecular diagnostics and genetic engineering experiments, as well as bio-health care ingredients comprise N-phytosphingosine and vitamin K2. The company also develops drug candidates for wet and dry macular degeneration, inflammatory bowel disease, anticancer, oral mucositis, nonalcoholic steatohepatitis, diabetic macular edema, and dry eye indications.
HLB Genex, Inc. Fundamentals Summary
| A187420 fundamental statistics | |
|---|---|
| Market cap | ₩80.23b |
| Earnings (TTM) | ₩22.59b |
| Revenue (TTM) | ₩43.37b |
Is A187420 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A187420 income statement (TTM) | |
|---|---|
| Revenue | ₩43.37b |
| Cost of Revenue | ₩28.33b |
| Gross Profit | ₩15.04b |
| Other Expenses | -₩7.55b |
| Earnings | ₩22.59b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 749.05 |
| Gross Margin | 34.67% |
| Net Profit Margin | 52.09% |
| Debt/Equity Ratio | 78.2% |
How did A187420 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/08 05:12 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HLB Genex, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.